GLP-1 medicines in India: the semaglutide and tirzepatide brands, the generics and who makes them

According to the US labels, semaglutide switches on the receptor for GLP-1, a natural gut hormone, and tirzepatide switches on two hormone receptors, GIP and GLP-1^12,13.

Brands in India in launch order, from Indian reports, filings and minutes of CDSCO, India's drug regulator^2,7,14. The list is not complete. Reports differ on the number of generic brands^1,15.

Facts checked on 21 October 2026.

This page leaves out two older GLP-1 medicines, dulaglutide and liraglutide. According to Pharmarack, they held about 4 % and 2 % of Indian GLP-1 sales in the year to April 2026¹.

Novo Nordisk's patent on semaglutide expired in India on 20 March 2026, and generic brands went on sale that weekend^6,20,21. Makers and brands, as reported at launch:

• Natco: Semanat and Semafull, in multi-dose vials^14,22.
• Eris: Sundae, for diabetes and weight management, in Eris's words^14,22.
• Dr Reddy's: Obeda, a pen for type 2 diabetes²³.
• Sun Pharma: Noveltreat, for weight management, and Sematrinity, for type 2 diabetes, in Sun's words²⁴.
• Glenmark: Glipiq¹⁴.
• Alkem: Semasize, Obesema and Hepaglide¹⁴.
• Zydus: Semaglyn, Mashema and Alterme (some reports write Altreme)^14,20. Lupin agreed to co-market the same injection as Semanext and Livarise²⁵.
• Torrent: Sembolic and Semalix, as tablets and injections²¹.
• MSN Laboratories: Semabest, a pre-filled pen, reported in April 2026²⁶.

Pharmarack counted 25 brands by April 2026, and a review by the Madras Diabetes Research Foundation (MDRF) counted nearly 40 companies¹. A July 2026 report counted more than 50 products approved by CDSCO¹⁵.

In July 2026, PTI reported that Torrent had announced a voluntary recall of select batches of its Semalix disposable pens, as a precaution²⁷. It was limited to select batches of the 2 mg and 4 mg pens made by Dr Reddy's, which had found a quality issue²⁷. Torrent said patients on treatment faced no risk, and that its other semaglutide products, including its tablets, were not affected^15,27. Medical Dialogues reported that Dr Reddy's voluntarily recalled select Obeda batches that were outside their quality specification, because of an impurity linked to the active ingredient¹⁵. Dr Reddy's said there were no patient safety concerns¹⁵. If a pack worries you, show it to your doctor or pharmacist.

We found no generic tirzepatide in India, and Bloomberg reported in April 2026 that the medicine is still under patent protection here⁹. Lilly launched Mounjaro on 20 March 2025, and the Mounjaro KwikPen, which holds 4 weekly doses, on 15 August 2025^7,16. Cipla launched Yurpeak, a second brand made by Lilly, on 11 December 2025, and Cipla said before launch that its price would match Mounjaro's^8,28.

PTI reported that Lilly launched Mounjaro in India for two uses²⁹. One is type 2 diabetes; the other, weight management for adults with a body mass index (BMI) of 30 or more, or 27 or more with a weight-related condition²⁹. In June 2026, CDSCO's expert committee said that removing these BMI limits was not appropriate, because obesity and overweight are defined differently for US and Asian populations³⁰. The page on who should not take GLP-1 medicines gives India's own BMI definition of obesity. If you want to weigh the two medicines, tirzepatide and semaglutide compared sets their trial results side by side.

India has semaglutide tablets for type 2 diabetes, but we found no Indian launch of the Wegovy pill or of orforglipron, two weight-loss tablets approved in the US^{5,12,31,32,33}. Rybelsus, from Novo Nordisk, comes in 3, 7 and 14 mg strengths, and its US label approves it for type 2 diabetes, not for weight loss^5,34. The generic tablets of Torrent and Sun Pharma had CDSCO committee recommendations for type 2 diabetes^30,35. Torrent says it was the first company in India to launch generic oral semaglutide, and Dr Reddy's launched its Obeda tablets on 20 May 2026^19,21. Dr Reddy's says CDSCO approved them after a Phase III study in 288 people with type 2 diabetes in India¹⁹. A Phase III trial tests a medicine in a large group of patients.

For the Wegovy pill (semaglutide 25 mg), no Indian approval was found either, so this page gives no dose schedule for oral Wegovy³². Medical Dialogues reported a positive CDSCO expert-committee recommendation for orforglipron (Foundayo in the US) in June 2026^31,33. Our page on how GLP-1 tablets are taken in India has the details.

Novo Nordisk cut its Indian prices from 1 April 2026: according to Storyboard18, the cut averaged about 24 % for Ozempic and 27 % for Wegovy across all strengths³⁶. In Novo Nordisk's price table, the Wegovy 2.4 mg price did not change³⁷. Each row keeps its source's unit, so before you compare two rows, check that the units match.

Indian prices as reported by the source in each row, with its date^10,38,39. Prices change. They are not an offer.

Prices checked on 21 October 2026. MRP is the maximum retail price printed on the pack.

The GST Council cut GST on most medicines from 12 % to 5 % from 22 September 2025⁴⁰.

Every generic brand contains semaglutide, the active ingredient of Wegovy and Ozempic^2,4,14. PharmEasy says the brands can still differ in strength, form, supporting clinical data and approved indication, that is, the use the regulator accepted¹¹.

In January 2026, CDSCO's committee recommended the generic injections of MSN and Natco, and Torrent's tablets, for type 2 diabetes, not for weight management³⁵. For the two injections, it first accepted their Phase III trial reports in type 2 diabetes³⁵. Sun Pharma says Noveltreat is for weight management, and Zydus says its injection is approved for obesity as well as diabetes^20,24.

Natco launched multi-dose vials, while Zydus uses a 15 mg/3 ml cartridge in a reusable pen, so a change of brand can mean a different device^14,20,22. Your doctor chooses the medicine, the dose and any change of brand. The semaglutide dose schedule sets out the dose steps, and the semaglutide side-effects guide gives the trial rate of each side effect.

PharmEasy says all semaglutide brands in India are Schedule H prescription medicines, and that Mounjaro cannot be sold over the counter^10,11.

Sources differ on who may write that prescription. A health-ministry release of March 2026 says GLP-1 weight-loss drugs were approved on condition of prescription by endocrinologists and internal medicine specialists, and for some indications by cardiologists only⁴¹. A government warning, reported in March 2026, says generic semaglutide must be sold only on a registered medical practitioner's prescription⁴². For tirzepatide, CDSCO's expert committee recommended a specialist-only condition in 2023; it is an approval condition, not a confirmed national rule⁴³.

CDSCO's advisory of 10 March 2026 prohibits surrogate advertisements and any indirect promotion of GLP-1 weight-loss drugs that could mislead consumers or encourage off-label use⁴¹. A surrogate advertisement promotes a product without naming it. Off-label use is use outside the approved indication.

In April 2026, Reuters reported that Haryana's drug regulator had seized more than 260 suspected counterfeit Mounjaro pens near New Delhi⁴⁴. Reuters could not verify this official claim⁴⁴. A government backgrounder advises you to obtain these medicines with a prescription, and only through legitimate, regulated channels⁴⁵.

Some products carry "GLP" in the name but contain no GLP-1 medicine. According to its PharmEasy listing, Glp 1mg Tablet from Intra Labs contains glimepiride 1 mg, a type 2 diabetes medicine⁴⁶. The listing names weight gain among its side effects, and the US glimepiride label warns that it can cause severe low blood sugar^46,47. Sweating and shaking are signs; the NHS says to treat low blood sugar quickly^48,49. Then tell your doctor. If someone may have very low blood sugar and is not responding normally, or is unconscious, call 112^49,50. Give an unconscious person nothing to eat or drink⁴⁹. If you see "GLP" on a pack, check the salt (medicine) name, not only the brand.

On 8 October 2026, FSSAI, India's food regulator, issued notices over the health claims of a protein supplement with "GLP" in its name, Indiantelevision.com reported⁵¹. The notices are not a final finding⁵¹. See GLP-1 supplements and patches for these products.

Is Ozempic another name for semaglutide? Ozempic is a brand name. Semaglutide is the medicine inside it⁴. In India, Ozempic is sold for type 2 diabetes, and Novo Nordisk sells its 2.4 mg weight-management dose as Wegovy¹⁸.

Is Wegovy available in India? Yes, as an injection^2,17. Novo Nordisk launched it on 24 June 2025². We found no Indian launch of the Wegovy pill up to 20 October 2026³².

Is Ozempic available in India? Yes, for type 2 diabetes¹⁸. Novo Nordisk launched it here on 12 December 2025⁴. Abbott announced a second Ozempic brand, Extensior, in February 2026⁵².

Do I need a prescription? Yes. PharmEasy lists Mounjaro and every semaglutide brand as Schedule H prescription medicines^10,11.

How much does generic semaglutide cost? An MDRF review reported on 24 September 2026 put it at ₹2,000 to ₹3,500 a month, by maker³⁹.

Is there a generic Mounjaro in India? We found none. Bloomberg reported in April 2026 that tirzepatide is still under patent protection in India⁹.

Talk to a Zelta specialist about whether any of these medicines suits you.